Bevacizumab, a recombinant humanized IgG1 antibody, has been widely used for the treatment of metastatic colorectal cancer and non–small cell lung cancer as a kind of anti-angiogenic agent by inhibiting effects of vascular endothelial growth factor (VEGF) (3, 4). Here, VEGFA is linked to metastatic colorectal cancer.